News UCB brings first therapy for rare disease TK2d to EU The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
News UCB closes on first EU OK for TK2d therapy UCB gets an EU recommendation for the first therapy for thymidine kinase 2 deficiency (TK2d), plus other CHMP decisions.
News CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.
News UK MHRA authorises orforglipron private prescription Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.